Cardiac Pharmacology: Difference between revisions

Cardiac Pharmacology (view source)

1,107 bytes removed , 27 May 2013

467

edits

@@ Line 124: / Line 124: @@
 |-
 !Drug
-!Drugs that ↑ drug action
+!Drugs that <big>↑</big> drug action
-!Drugs that ↓ drug action
+!Drugs that <big>↓</big> drug action
 |-
 !Digoxin
@@ Line 506: / Line 506: @@
 |Hyperlipidaemias of types IIa, IIb, III, IV and V
 |Gemfibrozil: 0.9-1.2mg daily
-|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite>
+|Gastro-intestinal
-|-
-|Ezetimibe
-|Primary and familial hyper-cholesterolaemia
-|10mg once daily
-|Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis<cite>Esc44</cite>
-|}
 ==References==